Amgen (AMGN) : Candriam Luxembourg S.c.a. reduced its stake in Amgen by 15.94% during the most recent quarter end. The investment management company now holds a total of 588,715 shares of Amgen which is valued at $100,481,876 after selling 111,618 shares in Amgen , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Amgen makes up approximately 2.55% of Candriam Luxembourg S.c.a.’s portfolio.
Other Hedge Funds, Including , Artemis Investment Management Llp reduced its stake in AMGN by selling 67,538 shares or 36.78% in the most recent quarter. The Hedge Fund company now holds 116,113 shares of AMGN which is valued at $19,818,167. Amgen makes up approx 0.52% of Artemis Investment Management Llp’s portfolio.First National Bank Sioux Falls boosted its stake in AMGN in the latest quarter, The investment management firm added 68 additional shares and now holds a total of 168 shares of Amgen which is valued at $28,674. Amgen makes up approx 0.09% of First National Bank Sioux Falls’s portfolio.Pennsylvania Trust Co reduced its stake in AMGN by selling 186 shares or 0.18% in the most recent quarter. The Hedge Fund company now holds 101,908 shares of AMGN which is valued at $16,636,481. Amgen makes up approx 1.31% of Pennsylvania Trust Co’s portfolio.Palladium Partners boosted its stake in AMGN in the latest quarter, The investment management firm added 2,739 additional shares and now holds a total of 100,956 shares of Amgen which is valued at $16,481,067. Amgen makes up approx 1.45% of Palladium Partners’s portfolio.Toth Financial Advisory Corp boosted its stake in AMGN in the latest quarter, The investment management firm added 5,469 additional shares and now holds a total of 7,244 shares of Amgen which is valued at $1,117,604. Amgen makes up approx 0.34% of Toth Financial Advisory Corp’s portfolio.
Amgen opened for trading at $171.57 and hit $172.26 on the upside on Friday, eventually ending the session at $172.03, with a gain of 0.44% or 0.75 points. The heightened volatility saw the trading volume jump to 31,21,594 shares. Company has a market cap of $129,232 M.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Investors should note that on Jul 22, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced Aug 15, 2016 as the ex-dividend date and fixed the record date on Aug 17, 2016. The payable date has been fixed on Sep 8, 2016.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.